---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-089566"
form_type: "8-K"
ticker: "ADVB"
cik: "0001941029"
company_name: "Advanced Biomed Inc."
filed_at: "2025-09-19T23:59:59+00:00"
generated_at: "2026-05-17T06:09:15.915004+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Advanced Biomed launches A+PerfusC 3D cell culture platform for precision medicine

## Summary
- A+PerfusC is a compact perfusion 3D cell culture incubator with automated perfusion and environmental control, mountable on a microscope for real-time observation.
- System supports up to 12 days continuous culture, 8 independent channels per plate, 600 tumor spheroids per row, and 4,800 spheroids per plate.
- Global 3D cell culture market valued at $2.32B in 2025, projected to exceed $4.71B by 2030 (CAGR >15.6%) per Mordor Intelligence.
- Mass-production development is ongoing; commercialization will follow finalization of mass production and quality control standards.
- Potential applications include personalized oncology, drug screening, regenerative medicine, organoid studies, and stem cell research.

## SEC filing metadata
- accession: 0001213900-25-089566
- form_type: 8-K
- ticker: ADVB
- cik: 0001941029
- company_name: Advanced Biomed Inc.
- filed_at: 2025-09-19T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1941029/000121390025089566/0001213900-25-089566-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1941029/000121390025089566/ea0258116-8k_advanced.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-089566
- JSON: https://secwatch.observer/filing/0001213900-25-089566.json
- Plain text: https://secwatch.observer/filing/0001213900-25-089566.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.